Objective: To determine the incremental cost‐effectiveness of clopidogrel plus aspirin (C+ A)
compared with aspirin (A) alone during the Clopidogrel for High Atherothrombotic Risk and …

Atherothrombosis is the most common cause of an acute ischemic event. Antiplatelet agents
form the cornerstone of atherothrombosis prevention. The purpose of this article is to review …

BACKGROUND: Clopidogrel is a more potent antiplatelet agent than aspirin, resulting in
greater clinical efficacy in patients with atherothrombotic disease. Furthermore, the …

Background Both aspirin and clopidogrel reduce the rate of cardiovascular events in
patients with coronary heart disease. We estimated the cost effectiveness of the increased …

The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management,
and Avoidance (CHARISMA) study (N Engl J Med 2006; 354: 1706-1717, J Am Coil Cardiol …

Objectives To quantify the impact of clopidogrel plus aspirin on the individual outcomes of
death, myocardial infarction, or stroke in patients with established cardiovascular disease, or …

Background: Although clopidogrel plus aspirin is more effective than aspirin alone in
preventing subsequent vascular events in patients with unstable angina, the cost …

BACKGROUND: When used as an alternative to or in addition to aspirin, clopidogrel has
been demonstrated by some but not all randomized controlled trials to be effective in …

Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been
studied in a broad population of patients at high risk for atherothrombotic events. Methods …

Objectives: The purpose of this study was to determine the possible benefit of dual
antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or …